From the Chief Medical Officer **Dr Michael McBride**



Circular HSC (SQSD) (NICE CG182) 21/14

Subject: NICE Clinical Guideline CG182 – Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care

Circular Reference: HSC (SQSD) (NICE CG182) 21/14

For action by:

Chief Executive of HSC Board – for distribution to:

All HSC Board Directors – for cascade to relevant staff

Director of Integrated Care, HSC Board – **for cascade to**:
Head of Pharmacy and Medicines Management
Family Practitioner Services Leads – for cascade to relevant
Family Practitioner groups

Chief Executive of Public Health Agency – for distribution to:

Director of Public Health and Medical Director – for cascade to relevant staff

Director of Nursing and AHPs - for cascade to relevant staff

Chief Executives of HSC Trusts – for distribution to:

Medical Directors – for cascade to relevant staff Directors of Nursing – for cascade to relevant staff Heads of Pharmaceutical Services – for cascade to relevant staff

Directors of Acute Services – for cascade to relevant staff HSC Clinical and Social Governance Leads Directors of Social Services – for cascade to relevant staff Directors of Finance – for cascade to relevant staff

Chief Executive, Regulation & Quality Improvement Authority – for cascade to: relevant independent healthcare establishments

Chief Executives of HSC Special Agencies and NDPBs

For Information to:

Chair of HSC Board Chair of Public Health Agency Chairs of HSC Trusts Chair of RQIA NICE Implementation Facilitator NI Members of NI NICE Managers' Forum

Summary of Contents:

This guideline updates and replaces NICE clinical guideline 73. It offers evidence-based advice on the care and treatment of people with chronic kidney disease.

Enquiries:

Any enquiries about the content of this Circular should be addressed to:

Standards & Guidelines Quality Unit DHSSPS Room D1.4 Castle Buildings Stormont Estate BELFAST BT4 3SQ

SGU-NICEGuidance@dhsspsni.gov.uk

Date of Issue: 15 September 2014

Related documents: HSC (SQSD) 3/13

Superseded documents

HSC (SQSD) (NICE) 19/09 CG 73

Status of Contents:

Action

Implementation:

As per circular. Generally, Clinical Guidelines should be implemented within 12 months of endorsement.

Additional copies:

Available to download from

http://www.dhsspsni.gov.uk/index/phealth/sqs/sqsd-guidance.htm



Dear Colleagues

NICE Clinical Guideline CG182 - Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care (http://www.nice.org.uk/guidance/CG182)

The Department has recently reviewed the above NICE guidance and has formally endorsed it as applicable in Northern Ireland.

In accordance with the process outlined in circular HSC (SQSD) 3/13 (http://www.dhsspsni.gov.uk/hsc_sqsd_3_13.pdf), the following actions should be taken

1. HSC Board / PHA

- a. Identify a Professional Lead who will consider the commissioning implications of the Clinical Guideline and co-ordinate with any other relevant commissioning teams. This Lead will identify any areas where regional planning / investment / commissioning are required, or where there is material risk to safety or quality. These will then be actioned immediately through normal commissioning arrangements or through bespoke arrangements reflecting the nature of the issue / risk.
- b. Ensure that relevant guidance is sent to the appropriate Family Practitioners.
- c. Seek positive assurance from the HSC Trusts that the required initial actions have been undertaken within a 3 month period, and that the Guideline has been implemented within a further 9 months (unless otherwise notified by the HSC Trusts).
- d. Where significant investment/ commissioning needs cannot be met within the usual timeframe, agree appropriate arrangements with HSC Trusts. Report to DHSSPS as required at 6 monthly accountability meetings.

2. HSC Trusts

- a. Proceed with targeted dissemination, agree a clinical/management lead to coordinate implementation and consider what has to be done to achieve implementation using a risk based assessment and baseline review as appropriate to support planning. These initial actions should be undertaken within a three month period.
- b. Implement the Guideline within a further 9 months (apart from any elements where significant issues have been raised with the HSC Board/PHA).
- c. Provide positive assurances to the HSC Board that required initial actions have been taken within the 3 month planning period and that the Guideline has been implemented within a further 9 months, where appropriate.
- d. Where significant investment/ commissioning needs cannot be met within the usual timeframe, notify the HSC Board/PHA at the earliest opportunity through the bi-monthly director level meetings and agree appropriate arrangements with them to achieve implementation.

3. RQIA

a. Disseminate the Guideline to the independent sector as appropriate.

4. HSC Special Agencies and NDPBs

a. Take account of this Guideline in training and other developments as appropriate.

To inform the planning process, please find attached details from the Departmental review including estimates of costs / savings based on the NICE costing template, where this is applicable. You should also consider and take account of other relevant Departmental policies and strategies in your planning, as well as any legislative / policy caveats identified in the course of the Departmental review.

A full current list of NICE guidance endorsed for application in Northern Ireland can be found on the Department's website (http://www.dhsspsni.gov.uk/index/phealth/sqs/sqsd-guidance-nice-guidance.htm).

Dr Michael McBride Chief Medical Officer

Mudrael My Guelo

Appendix 1

Endorsed NICE guidance - Details from Departmental review

Reference Number	NICE Clinical Guidelines - CG182
Title	Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care
Summary of guidance	This guideline(published by NICE in July 2014) updates and replaces NICE clinical guideline 73 (endorsed by Department March 2009)
Number of people expected to take up or benefit from the service / therapy	Unable to calculate for NI.
Costs / savings associated with	Unable to calculate for NI.
implementation	It is expected that the use of ACR and cystatin C testing to improve the diagnosis of people with CKD will lead to increased costs. However, the improved classification of people with CKD is likely to reduce the number of people requiring treatment and monitoring and will result in some savings. Overall, it is thought that fully implementing this guidance in NI will present some cost saving opportunities but this cannot be estimated with any degree of certainty.
Related strategically relevant DHSSPS policies	None
Inter-Departmental interest	None
Legislative / policy caveats	This advice does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case. The Mental Capacity Act 2005 and the Department
	of Health document 'Reference Guide to Consent for Treatment or Examination' do not apply in NI, but

work is under way to bring forward similar legislation for NI, incorporating mental capacity and mental health provisions. The DHSSPS guidance 'Reference Guide to Consent for Examination, Treatment or Care (2003)', which is available on the DHSSPS website, gives advice on determining whether a person has capacity and on what action may be taken where the person lacks capacity. Available from:

http://www.dhsspsni.gov.uk/consent-referenceguide.pdf